Modalities

mRNA Therapeutics and Vaccines

mRNA technologies are changing how vaccines and therapeutics are developed, manufactured, and scaled. Their speed, adaptability and modular design are creating new possibilities across infectious disease, oncology, rare disease, and personalized medicine.

Visualization of messenger RNA (mRNA) molecular structure used in mRNA therapeutics and vaccine manufacturing workflows, including purification, LNP formulation, and scalable bioprocess development.

Supporting the Next Generation of mRNA Therapeutics and Vaccines

Successful mRNA manufacturing depends on more than the molecule itself. It requires scalable and reproducible processes that protect these sensitive products while maintaining efficiency from process development through commercial production. At Repligen, we collaborate with biopharmaceutical manufacturers to help streamline complex mRNA workflows. Our integrated solutions for filtration, chromatography, fluid management, and process analytics solutions are designed to enhance process consistency, accelerate scale-up, and strengthen manufacturing confidence across the entire development and production lifecycle.

What Is mRNA?

Messenger RNA (mRNA) is a naturally occurring molecule that carries instructions for protein production within cells. In therapeutics and vaccines, synthetic mRNA is used to direct cells to produce a specific protein that drives a desired biological response.

For vaccines, mRNA enables cells to produce antigens that stimulate the immune system to recognize and respond to disease.

Messenger RNA (mRNA) molecule illustration representing mRNA vaccine development, therapeutic discovery, and scalable bioprocess manufacturing for advanced genetic medicines.

For therapeutics applications, mRNA enables the transient expression of proteins and other biologics, supporting a wide range of innovative treatment approaches, including:

  • Cancer immunotherapies
  • Protein replacement therapies
  • Gene editing and gene modulation approaches
  • Regenerative medicine & tissue repair
  • Personalized and precision medicines
  • Rare and genetic disease treatments
  • In vivo cell engineering and cell therapies
  • Immune modulation and autoimmune disease therapies

Because mRNA platforms can be designed and adapted quickly, they offer an efficient path for developing new therapies and responding to emerging health needs.

Common Challenges in mRNA Process Development

mRNA manufacturing introduces unique process development and purification challenges. The molecules are sensitive, the workflows are complex, and process consistency becomes increasingly important as manufacturing scales.

Teams developing mRNA therapies need to balance several priorities at once:

  • Protecting product integrity
  • Removing product and non-product related impurities
  • Maintaining recovery and yield
  • Scaling processes confidently
  • Improving process visibility and control

Addressing these challenges early can help reduce process variability, improve manufacturability, and accelerate development timelines.

Maintaining mRNA Integrity

mRNA molecules are highly sensitive to degradation, shear exposure, enzymatic activity, and environmental conditions. Even small process inconsistencies can impact product quality and recovery.

Manufacturers need process technologies that support gentle handling while maintaining throughput and scalability.

Following in vitro transcription (IVT), manufacturers must efficiently remove process and product-related impurities including:

  • Double-stranded RNA (dsRNA)
  • Residual DNA templates
  • Residual Enzymes and host-cell proteins
  • Unincorporated nucleotides and reaction components
  • RNA aggregates, truncated species, and fragments

Effective impurity removal is essential to ensure product quality, safety, potency, and regulatory compliance while supporting robust and scalable manufacturing processes.

Processes that perform well at laboratory scale can behave differently during process scale-up and commercial manufacturing. As production volumes increase, manufacturers encounter challenges such as:

  • Membrane fouling and filter performance variability
  • Flux variability and process inconsistencies
  • Product loss and reduced recovery yields
  • Mixing and fluid-handling inconsistencies
  • Variability in LNP formation and encapsulation efficiency

Developing scalable, robust workflows early in the process helps reduce risk during scale-up, technology transfer, and commercial manufacturing while improving process consistency and manufacturing efficiency.

As mRNA manufacturing evolves toward more intensified, automated, and connected operations, real-time process monitoring and analytics are becoming increasingly important.Manufacturers are seeking solutions that enable them to:

  • Reduce manual sampling and offline testing
  • Accelerate data-driven decision-making
  • Improve process consistency and reproducibility
  • Support real-time monitor and process control strategies
  • Enable more efficient scale-up and tech transfer

Enhanced process visibility helps manufacturing teams respond more quickly to process deviations, optimize performance, and operate with greater confidence.

mRNA Manufacturing Process

mRNA manufacturing integrates synthesis, purification, formulation, and final processing into a highly controlled and scalable workflow. Because mRNA is sensitive to enzymatic degradation, shear stress, and process variability, each manufacturing step plays a critical role in ensuring product quality, potency, safety, and reproducibility.

Typical mRNA Manufacturing Workflow

Each stage of the workflow contributes to overall process robustness, scalability, and product quality, making integrated process control and analytical monitoring increasingly important across mRNA manufacturing.

Each step plays an important role in overall process performance, product quality, and scalability.

Plasmid DNA (pDNA) Template Preparation

Production, amplification, linearization, and purification of plasmid DNA templates used for in vitro transcription (IVT). High-quality pDNA is essential for transcription efficiency and final product consistency.

In Vitro Transcription (IVT)

Enzymatic synthesis of mRNA using RNA polymerase, nucleotides, and the linearized DNA template. This step generates the target mRNA transcript and is a key determinant of yield and product quality.

Enzymatic Processing and mRNA Modification

Post-transcription processing steps such as 5’ capping, poly(A) tail optimization, and, in some workflows, enzymatic cleanup or nucleotide modification. These steps help improve mRNA stability, translation efficiency, and reduce innate immune activation.

Purification

Removal of process and product-related impurities, including dsRNA, proteins, residual DNA, templates, enzymes, proteins, endotoxins, free nucleotides, and truncated RNA species. Purification is critical for product safety, efficacy, and regulatory compliance.

Ultrafiltration and Diafiltration (UF/DF)

Concentration and buffer exchange operations are used to prepare purified mRNA for downstream formulation. UF/DF helps achieve target concentration, remove residual small molecules, and establish formulation-compatible buffer conditions.

Lipid Nanoparticle (LNP) Formulation

Encapsulation of mRNA into lipid nanoparticles using controlled mixing technologies. LNPs protect mRNA from degradation, support intracellular delivery, and strongly influence particle size, encapsulation efficiency, biodistribution, and overall therapeutic performance.

Sterile Filtration and Fill-Finish

Final sterile processing, filtration, aseptic filling and packaging steps performed prior to clinical or commercial distribution. These operations are essential for maintaining sterility, product integrity, and shelf stability.

Each step plays an important role in overall process performance, product quality, and scalability.

Lipid Nanoparticles (LNPs) in mRNA Therapeutics

Lipid nanoparticles are a critical part of mRNA delivery. Without protection, mRNA molecules degrade quickly in the body and are not efficiently delivered into cells. LNPs help protect the molecule and enable effective intracellular delivery.

Why LNPs Matter

Addressing these challenges early can help reduce process variability, improve manufacturability, and accelerate development timelines. Because of this, manufacturers often focus on improving control and reproducibility during formulation and mixing operations.

mRNA PrioritiesProcess conditions can influence:
Protecting product integrityParticle size distribution
Removing product and non-product related impurities efficientlyEncapsulation efficiency
Maintaining recovery and yieldProduct consistency
Scaling processes confidentlyAggregation behavior
Improving process visibility and control Scale-up performance

Repligen Solutions for mRNA Manufacturing

Repligen technologies are designed to help manufacturers improve process efficiency, maintain product quality, and scale manufacturing with greater confidence.

Tangential Flow Filtration for mRNA Purification

Tangential flow filtration (TFF) is widely used in mRNA workflows for:

  • Concentration
  • Diafiltration
  • Buffer exchange
  • Impurity removal

TFF plays an important role in preparing mRNA intermediates and final drug substance for downstream formulation and processing.

Careful optimization of membrane selection, flow conditions, transmembrane pressure (TMP), and process parameters is essential to maintain product integrity and process efficiency.

Repligen KrosFlo® RS 20 TFF system with integrated process controls for ultrafiltration and diafiltration (UF/DF), enabling efficient concentration, purification, and buffer exchange in biologics, mRNA, and cell and gene therapy manufacturing.

Common Challenges

Manufacturers often need to manage:

  • Flux decline during extended processing
  • Recovery loss and reduced recovery yields
  • Membrane fouling and throughput limitations
  • Product adsorption and nonspecific binding
  • Process reproducibility and scale-up consistency
  • Shear sensitivity of mRNA and LNP formulations

How Repligen Helps

Repligen solutions are designed to support:

  • High product recovery and yield retention
  • Gentle processing conditions for sensitive molecules
  • Scalable process development and manufacturing workflows
  • Improved process consistency and reproducibility
  • Flexible platform development from R&D through commercial scale
  • Integration with automated and intensified manufacturing strategies

Related Solutions

KrosFlo® Tangential Flow Filtration systems

KrosFlo® tangential flow filtration (TFF) systems by Repligen provide high-performance ultrafiltration/diafiltration (UF/DF) solutions across research, process development and GMP manufacturing. Engineered to streamline downstream processes, KrosFlo® TFF systems feature advanced automation capabilities, support most filter and membrane options, and can be integrated with advanced process analytics technologies.

Read More

TangenX® Flat Sheet Cassettes

KrosFlo® tangential flow filtration (TFF) systems by Repligen provide high-performance ultrafiltration/diafiltration (UF/DF) solutions across research, process development and GMP manufacturing. Engineered to streamline downstream processes, KrosFlo® TFF systems feature advanced automation capabilities, support most filter and membrane options, and can be integrated with advanced process analytics technologies.

Read More

Hollow Fiber Filters

Ideal for ultrafiltration and microfiltration of shear-sensitive modalities, Spectrum® Hollow Fiber Filters for TFF can accommodate the widest range of scales, membrane chemistries and pore sizes to maximize process outcomes.

Read More

Process Analytics and Real-Time Monitoring

As mRNA manufacturing processes become more integrated, automated, and data-driven, real-time analytics and process analytical technologies (PAT) are increasingly important for improving process understanding, consistency, and operational control.

Enhanced process monitoring can help reduce variability, improve manufacturing efficiency, and support more robust process development and commercial operations.

Repligen KrosFlo® RS 20 TFF system with integrated process controls for ultrafiltration and diafiltration (UF/DF), enabling efficient concentration, purification, and buffer exchange in biologics, mRNA, and cell and gene therapy manufacturing.

Common Challenges

Manufacturers often need better ways to:

  • Support process consistency and reproducibility during scale-up
  • Monitor concentration and critical process parameters in real time
  • Reduce reliance on manual sampling and offline testing
  • Improve process visibility across unit operations
  • Enable faster, data-driven decision-making
  • Advance toward real-time process control strategies

How Repligen Helps

Repligen PAT technology solutions are designed to support:

  • Real-time monitoring and in-line measurement capabilities
  • Improved process understanding and operational insight
  • Faster process development and optimization
  • More consistent manufacturing performance
  • Reduced manual intervention and offline analysis
  • Integration with automated and intensified bioprocess workflows

Related Solutions

PATsmart™ FlowVPX® System

Designed for GMP environments, the PATsmart™ FlowVPX® spectrophotometer delivers continuous, in-line concentration measurement during downstream processing, providing real-time data to actively control the process as it runs. This level of control is made possible by Variable Pathlength Technology (VPT), which enables accurate, dilution-free concentration measurement across development, scale-up, and GMP manufacturing.

Read More

PATsmart™ SoloVPE® PLUS System

UV-Vis Concentration Measurement for GMP and Non-GMP Testing The new PATsmart™ SoloVPE® PLUS System features patented variable pathlength technology (VPT), providing precise concentration measurements with no need for costly dilutions. This reliable solution delivers fast, accurate results with system-to-system, operator-to-operator, and site-to-site consistency, ensuring high-quality performance across various bioprocessing applications.

Read More

PATsmart™ FlowVPE® System

The PATsmart™ FlowVPE® System uses the power of Slope Spectroscopy for online process monitoring and PAT fields. Offering process insights and enabling innovation, the FlowVPE helps accelerate development, reduce risk, and increase process efficiency.

Read More

Chromatography Solutions for Impurity Removal

Purification strategies are critical for removing impurities while maintaining product integrity and process efficiency.

Repligen chromatography solutions help manufacturers build purification workflows.

Repligen KrosFlo® RS 20 TFF system with integrated process controls for ultrafiltration and diafiltration (UF/DF), enabling efficient concentration, purification, and buffer exchange in biologics, mRNA, and cell and gene therapy manufacturing.

Common Challenges

Manufacturers often need to manage:

  • Improve dsRNA removal
  • Increase purification efficiency
  • Simplify scale-up
  • Reduce process complexity

How Repligen Helps

Repligen solutions are designed to support:

  • Scalable
  • Reproducible
  • Flexible
  • Efficient to implement

OPUS® Pre-packed Chromatography Columns

Accelerate process development and scale-up with consistent performance, reduced operational complexity, and faster deployment from lab to commercial production.

Repligen OPUS pre‑packed chromatography columns shown in multiple sizes, designed for scalable downstream protein purification and bioprocessing applications.

Chromatography

Increase purification efficiency with systems, pre-packed columns, and resins engineered for modern biologics manufacturing. 

Repligen KRM 10 Chromatography System featuring an integrated OPUS 20 pre-packed column and dual-screen digital interface for automated large-scale protein purification and downstream bioprocessing.

Affinity Resins

Chromatography resins that deliver high binding capacity, and fast flow rates so biopharma teams purify antibodies, viral vectors, and new modalities with higher yield and better process economics.

Single-Use Fluid Management for Flexible Manufacturing

Single-use systems can help manufacturers improve flexibility while reducing operational complexity and contamination risk.Enhanced process monitoring can help reduce variability, improve manufacturing efficiency, and support more robust process development and commercial operations.

Common Challenges

Manufacturing teams are often focused on:

  • Reducing turnaround time
  • Simplifying changeovers
  • Supporting multiproduct facilities
  • Maintaining closed processing environments

How Repligen Helps

Repligen fluid management solutions are designed to support:

  • Flexible manufacturing operations
  • Faster deployment
  • Simplified workflows
  • Closed-system processing

ProConnex® Flow Paths

ProConnex® Flow Paths for TFF and Chromatography processes are single-use and engineered for optimum performance, reproducibility and time savings. System specific flow paths provide speed and reliability. Configured flow paths prioritize process requirements and sterility. ​

Repligen PCx single‑use flow paths assembled for bioprocessing applications, showing tubing, connectors, and integrated process components.

Single -Use Fluid Management

Move, mix, store, and transfer critical process fluids with single-use solutions designed for speed, sterility, and operational flexibility.​

Repligen ProConnex MixOne RG-X single-use mixing system featuring Metenova Zero Gravity technology and RG-V film for sterile, low-shear bioprocessing and vaccine manufacturing.

Fluid Management

Own your process with ProConnex® — streamlined fluid management solutions that reduces risk, improves consistency, and accelerates your path to production.​

Integrated fluid management solutions for bioprocessing

Supporting the Future of mRNA Manufacturing

As mRNA therapeutics continue to evolve, manufacturers are looking for process solutions that support:

 

Faster development timelines

Greater manufacturing flexibility

More consistent product quality

Scalable production strategies

Improved process control

Repligen works alongside biopharmaceutical manufacturers to help build manufacturing processes that are practical, scalable, and designed for long-term success.

Frequently Asked Questions

mRNA manufacturing is the process of producing messenger RNA therapeutics or vaccines through synthesis, purification, formulation, and sterile processing operations.

LNPs protect mRNA molecules and help deliver them into cells efficiently, improving stability and therapeutic performance.

Common impurities include dsRNA, residual DNA, proteins, enzymes, free nucleotides, and aggregates.

TFF is commonly used for concentration, diafiltration, and buffer exchange while helping maintain product recovery and process scalability.

Repligen provides filtration, chromatography, fluid management, and process analytics technologies that help manufacturers improve process consistency, scalability, and operational confidence.

Explore mRNA Quantification and Analytical Strategies for Development, Manufacturing, and Quality Control

Developing and manufacturing mRNA therapeutics requires analytical methods that can accurately quantify mRNA, support process development, and enable efficient quality control. As mRNA modalities continue to evolve, analytical teams face increasing pressure to generate reliable data while reducing workflow complexity and accelerating decision-making.

This collection of technical resources explores practical approaches to mRNA quantification and characterization across development, manufacturing, and QC environments. Learn how variable pathlength spectroscopy and slope spectroscopy can support direct measurement of mRNA in lipid nanoparticle (LNP) formulations, streamline method validation and transfer, reduce sample preparation requirements, and improve analytical efficiency. You'll also discover emerging strategies for dsRNA removal and quantitation that can help address the challenges associated with next-generation mRNA therapeutics.

Technical ResourcesWhat You'll Learn
Validation of mRNA concentration determination by slope spectroscopy technology: a matrixed approach This research article presents a matrixed validation strategy for measuring mRNA concentration using slope spectroscopy. It demonstrates how variable pathlength spectroscopy can support accurate, repeatable, and transferable mRNA concentration testing across multiple sample matrices, making it relevant for analytical development, QC, and lot release workflows.
Read More
Quantification of total mRNA content in LNP complexes using the SoloVPE® variable pathlength systemThis application note demonstrates a direct method for measuring total mRNA content in LNP formulations using the SoloVPE variable pathlength system. It focuses on overcoming common RiboGreen workflow challenges, including dilution, calibration curves, chemical disruption, and extended analysis time, while supporting faster total RNA assessment for LNP development, manufacturing, and QC.

Read More

Rapid and Nondestructive Total mRNA Quantification with Slope Spectroscopy for Conventional and UV-Absorbing Lipid NanoparticlesThis special report explores a nondestructive approach for measuring mRNA directly in intact LNPs, including more complex formulations with UV-absorbing lipid components. It highlights how slope spectroscopy and scatter correction can reduce sample manipulation, avoid dilution or extraction steps, and support faster mRNA-LNP formulation development and quality control.

Read More

Revolutionizing mRNA Concentration Measurement with Variable Pathlength Spectroscopy This educational resource focuses on method development and qualification for measuring total mRNA concentration after LNP encapsulation using variable pathlength spectroscopy. It positions the technology as a practical way to improve confidence and efficiency in mRNA analytical workflows, especially where rapid, accurate concentration measurement is needed after formulation into LNPs.

Read More

Strategies for dsRNA Removal and Accurate Quantitation in Emerging mRNA Modalities In this webinar, Rice University assistant professor Kelsey Swingle, PhD, provides a current overview of mRNA lipid nanoparticle therapeutics and Repligen senior scientist Nathaniel Clark, PhD, discusses emerging purification and quantitation techniques that work for the new generation of mRNA therapeutics beyond COVID-19 vaccines.

Read More